EP
SRPT icon

Elkfork Partners’s Sarepta Therapeutics SRPT Stock Holding History

Elkfork Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$22K Buy
286
+88
+44% +$10.4K ﹤0.01% 1026
2019
Q2 		$30K Hold
198
– – ﹤0.01% 1016
2019
Q1 		$24K Buy
198
+22
+13% +$2.83K ﹤0.01% 1013
2018
Q4 		$19K Buy
+176
New +$22K ﹤0.01% 981

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Elkfork Partners's SRPT Position: Q3 2019 in Review

Elkfork Partners increased its Sarepta Therapeutics (SRPT) stake by 44% in Q3 2019, buying an estimated $10.4K and bringing the position to 286 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

Elkfork Partners first reported a position in SRPT in Q4 2018 and has held it in 4 quarters since. The position peaked at $30K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Elkfork Partners held 286 shares of Sarepta Therapeutics worth $22K as of Q3 2019.
  • Elkfork Partners bought 88 Sarepta Therapeutics shares in Q3 2019, an estimated $10.4K.
  • Sarepta Therapeutics made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1026 holding.
  • Elkfork Partners first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Elkfork Partners's Sarepta Therapeutics position peaked at $30K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.